When antidepressants stop working: understanding treatment resistance
When traditional antidepressants fail to deliver relief, an estimated 20-30% of people living with depression meet the criteria for treatment-resistant depression (TRD), defined as an inadequate response to at least two different medications. This is a clinical reality affecting millions of Americans , yet many continue cycling through medication trials for months or years without exploring alternatives. The emotional toll of repeated failures—the hope invested in each new prescription, the disappointment when it doesn’t work—can compound the depression itself.
SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) often require weeks to months to show effects, if they work at all—and side effects like emotional blunting, sexual dysfunction , weight gain, and drowsiness can undermine quality of life for Manhattan residents seeking alternative depression treatment in New York.
After two, three, or even five failed antidepressant trials, the question shifts: is it time for a fundamentally different approach?
Non-medication depression treatment in Manhattan: clinical depression treatment without medication
Alternative depression treatment in New York encompasses device-based approaches like TMS and medication-assisted options like Spravato and IV (intravenous) ketamine that work through entirely different mechanisms than traditional antidepressants. Rather than slowly adjusting neurotransmitter levels over weeks, these treatments target neuroplasticity (the brain’s ability to form new neural connections) and can produce measurable changes within hours or days.
It’s important to clarify what “non-medication” means here. While daily pills are eliminated, some clinical depression treatment without medication options do involve medication—just delivered as episodic medical interventions under clinical supervision rather than taken home as prescriptions. You’re not developing a daily chemical dependency; you’re receiving precisely dosed therapeutic sessions.
TMS (transcranial magnetic stimulation) uses magnetic fields to stimulate specific brain regions associated with mood regulation. FDA-cleared for major depressive disorder since 2008, TMS now includes accelerated protocols—the SAINT protocol, cleared by the FDA in September 2022, condenses treatment into five consecutive days of intensive theta-burst stimulation.
Spravato (esketamine nasal spray) is FDA-approved specifically for TRD and covered by most insurance plans. You self-administer the nasal spray in a clinical setting and remain under observation for two hours afterward.
IV ketamine delivers 100% bioavailability with rapid relief within hours for many members. A single IV ketamine infusion produces 50-70% response rate in individuals with TRD. IV ketamine offers greater precision and control for clinicians compared to at-home options , which can be less predictable. Dosing is carefully titrated based on your response, vital signs are monitored throughout, and integration support is available immediately afterward.
The evidence hierarchy: ranking treatments by clinical data quality
FDA clearance represents the highest tier of evidence, requiring multiple randomized controlled trials (RCTs) demonstrating both safety and efficacy. TMS earned this clearance in 2008 for major depressive disorder after extensive double-blind trials. Spravato followed in 2019 specifically for TRD, backed by RCT data across 774 participants in pivotal trials.
IV ketamine sits in a different category: off-label use supported by strong RCT evidence. “Off-label” means prescribing FDA-approved medications for evidence-backed conditions not listed on the original label—a practice accounting for over 20% of US prescriptions . Ketamine itself is FDA-approved as an anesthetic and has been used safely in surgical settings for decades. Its use for depression is off-label, but a meta-analysis of 24 RCTs involving 1,877 participants shows response and remission rates (RR=3.01 and RR=3.70) that exceed many FDA-approved options.
Durability matters as much as initial response. Spravato’s SUSTAIN trials demonstrated that members maintaining treatment showed sustained improvement over 12 months. TMS follow-up data indicates that 12 months after treatment, many individuals maintain significant symptom reduction, though some require maintenance sessions. For IV ketamine, maintenance boosters—typically scheduled every 4-8 weeks after the initial series—help extend durability for many members, with response rates remaining high when integrated into an ongoing care plan.
Combination protocols represent emerging evidence with particularly compelling outcomes. A systematic review of TMS plus ketamine found response rates exceeding 80%, with sustained improvement across included studies—though sample sizes remain small and larger trials are needed to confirm these promising early results. In practice, TMS may “prime” neuroplastic pathways, making subsequent ketamine sessions more effective. Some Manhattan clinics sequence TMS first for 2-4 weeks, then introduce ketamine; others alternate modalities within the same week.
Understanding ketamine FDA approval and off-label use helps contextualize where regulatory status and clinical efficacy intersect. The detailed comparison of Spravato vs. IV ketamine clarifies both similarities and critical distinctions when you’re ready to choose between approaches.
A practical comparison: costs, timelines, and insurance in NYC
TMS typically requires 20-30 daily sessions spanning 4-6 weeks, with each session lasting 30-40 minutes. Accelerated protocols condense this timeline into 6 days, though availability in Manhattan remains limited. Insurance coverage is partial under many plans, with you often responsible for copays that accumulate over multiple weeks.
Spravato follows a structured escalation schedule: twice-weekly sessions for four weeks, then weekly and eventually biweekly sessions. Each visit requires approximately 2.5 hours when accounting for observation time.
Coverage by Medicare, Aetna, Cigna and other major insurers makes Spravato the most accessible option financially. Prior authorization is typically required.
IV ketamine through Nushama’s protocol involves 6 infusions over 3-6 weeks, with each infusion lasting 40-60 minutes followed by integration support. The entire visit spans approximately 2 hours. Nushama currently offers IV ketamine and Spravato (esketamine), with TMS launching in April 2026 to create a comprehensive multi-modality treatment program under one roof. Because IV ketamine for depression remains off-label, it is private-pay, with financing options available.
Reviewing success rates provides detailed outcome data that can inform your treatment selection.
Why the setting matters: preparation and integration
Medicine acts as a catalyst, but the support system—preparation, set and setting, and integration coaching—determines durability of results. This structured framework distinguishes comprehensive programs from infusion-only clinics that deliver medication without the surrounding structure that translates physiological changes into lasting shifts.
Medical screening ensures you’re an appropriate candidate. Contraindications include uncontrolled hypertension, history of psychosis or schizophrenia, active substance use disorder, unstable cardiac conditions, and certain medication interactions. Your care team will review your full medical history before proceeding.
Preparation involves intention-setting: identifying what you hope to gain, what patterns you’re ready to release, and what support you’ll need. Set refers to your mindset and emotional readiness; setting describes the external environment—lighting, sound, comfort, and the presence of trained clinicians who can guide you through difficult moments.
During the session, continuous vital monitoring and skilled staff shape a safe environment for inward focus. For ketamine therapy, dissociation—a feeling of detachment from one’s body or environment—can feel disorienting, and having clinicians who understand this process makes the experience more therapeutic. Many members describe these sessions as creating space for insights that feel deeply personal and sometimes spiritual in nature.
Integration is where insights become action. Integration coaching helps you translate new perspectives into concrete changes: therapy adjustments, boundary-setting, or shifts in daily routines.
Nushama’s approach combines medical supervision with therapeutic support at every stage—because neuroplasticity creates the opportunity for change, but integration determines whether that change lasts.
FAQs
Is ketamine therapy covered by insurance?
Spravato is covered by most major insurance plans including Medicare, while IV ketamine is typically private-pay due to its off-label status. Prior authorization is generally required for Spravato.
What is the difference between Spravato and IV ketamine?
Spravato is FDA-approved, insurance-covered nasal spray with standardized dosing, while IV ketamine offers 100% bioavailability, individualized dosing, and deeper experiential processing that many clinicians believe enhances therapeutic outcomes.
How quickly does the treatment work?
Many members report relief within hours or days of their first sessions, particularly with IV ketamine. TMS typically requires several weeks before noticeable improvement, while Spravato often shows effects within the first few sessions.
What is the most effective alternative depression treatment in New York?
IV ketamine produces 50-70% response rates in people with TRD, and combination protocols involving TMS plus ketamine achieve 80% response rates in research settings, making them among the most effective evidence-based options available.
Who is a good candidate for these treatments?
Ideal candidates have tried at least two antidepressants without adequate relief, are medically cleared for the specific treatment, and can commit to the full protocol including preparation and integration support.
Finding the right path forward
Evidence-based alternatives—TMS, Spravato, and IV ketamine—are available across Manhattan for individuals whose medications have not delivered relief. These treatments rest on decades of research, FDA clearances, and growing real-world evidence.
Prioritize providers offering medical supervision, thorough intake, and integration support. Preparation, environment, and structured follow-up determine whether initial relief becomes lasting remission.
Nushama offers comprehensive ketamine therapy with medical oversight, integration coaching, and a setting designed for therapeutic work.
Speak with our care team to discuss your specific history and treatment eligibility.
